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Summary
Background Observations in the UK at the end of the last century found
increasing trends of asthma prevalence over time. However, it has been
reported that the number of new cases of asthma presenting to general
practice has declined, especially among younger children.
Aim To study national trends in the epidemiology of asthma.
Methods A cross-sectional observation analysis was performed using the
QRESEARCH database, which is one of the world’s largest national
aggregated health databases containing records from 422 English practices
yielding 30 million patient-years of observation. Data was extracted on
333,294 individuals with a recorded diagnosis of asthma and calculated
annual age–sex standardized incidence, lifetime period prevalence and
asthma-related prescribing rates for each year from 2001–2005.
Results The incidence rate of asthma decreased in all patients (2001: 6.9
(95% confidence intervals [CI] 6.8–7.0); 2005: 5.2 (95% CI 5.1–5.3) per 1000
patient-years, p<0.001), but most particularly in children under 5 years of age
(–38.4%) where a decrease in the lifetime prevalence of asthma (–34.3%) was
also found. However, the lifetime prevalence rate of asthma for adults
increased (15–44 years: 23.3%; 45–64 years: 27.7%; >65 years: 21.5%) with an
estimated 5,658,900 (95% CI 5,639,700–5,678,200) or approximately one
person in nine having being diagnosed with asthma in England. The number
of asthma-related prescriptions also increased over the study period (17.1%),
such that in 2005 an estimated 32,577,300 (95%CI 32,531,600–32,623,000)
prescriptions were issued.
Conclusions This large national study reveals that the rate of new diagnoses
of asthma appears to have passed its peak; however, the number of adults with a
lifetime asthma diagnosis continues to rise. Whether these trends are genuine or
are a result of the introduction of incentives and guidelines to improve
identification and recording of asthma or changing diagnostic trends is a question
with important public health implications and one, therefore, that warrants
detailed further enquiry.
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Introduction
Asthma is one of the most important chronic con-
ditions in the UK, affecting patients’ quality of life
and posing a high level of burden on health ser-
vices.1 Observations in the UK at the end of the last
century found increasing trends of asthma preva-
lence over time.2,3 However, it has been reported
that the number of new cases of asthma presenting
to general practice has declined, especially among
younger children.4
This study of national trends in the epidemiol-
ogy of asthma was commissioned by the Chief
Medical Officer for England because of growing
concern about the high prevalence, disease burden
and healthcare costs (£800 million [V880 million]
annually) associated with asthma (and other res-
piratory disorders) and is being used to inform
policy deliberations on allergy and respiratory ser-
vice provision in England.5
Methods
Version 10 of the QRESEARCH database was used
for these analyses. This database contains broadly
representative anonymized aggregated health data
derived from 422 primary care practices throughout
England. Data were available for each year during
the period 1 January 2001–31 December 2005, these
comprising of between 2.8 and 3 million individual
patients who collectively contributed over 30 mil-
lion patient-years of observation. All individuals
resident in England (including children) are regis-
tered with primary care, which is free at the point of
contact. The methods used to collect primary care
data for the QRESEARCH database have been pre-
viously described.6–9
Patients were characterized by gender, age (under
5 years; 5–14 years; 15–44 years; 45–65 years; >65
years), deprivation (area-based Townsend depriva-
tion quintiles), andwere included in the analysis year
if they were registered for the entire year of study.
Patients with incomplete data (i.e. temporary resi-
dents, newly-registered patients and those who
joined, left or died during the study year) were
excluded.
The patients analysed in this studywere consid-
ered to have asthma if they had a relevant
computer-recorded diagnostic Read code (Box 1)
in their electronic health record during the time
period of interest (occupational asthma was not
included in this analysis). Incidencewas defined as
the number of patients with a new case of asthma
diagnosed in a specific year, with the denominator
being the number of patient-years of observation
(calculated from the number of patients registered
with practices and their length of registration).
Lifetime prevalence was defined as the number of
people with asthma ever recorded on at least one
occasion in the general practice (GP) records; the
denominator used to calculate the lifetime preva-
lence rate was the number of patients registered
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Box 1
Asthma Read codes used in the analysis
Read
codes
Read term
H33 Asthma
H33-1 Bronchial asthma
H330 Extrinsic (atopic) asthma
H330-1 Allergic asthma
H330-2 Childhood asthma
H330-3 Hayfever with asthma
H330-4 Pollen asthma
H3300 Extrinsic asthma without status
asthmaticus
H3300-1 Hay fever with asthma
H3301 Extrinsic asthma with status
asthmaticus
H3301-1 Extrinsic asthma with asthma attack
H330z Extrinsic asthma NOS
H331 Intrinsic asthma
H331-1 Late onset asthma
H3310 Intrinsic asthma without status
asthmaticus
H3311 Intrinsic asthma with status
asthmaticus
H3311-1 Intrinsic asthma with asthma attack
H331z Intrinsic asthma NOS
H332 Mixed asthma
H333 Acute exacerbation of asthma
H334 Brittle asthma
H33z Asthma unspecified
H33z-1 Hyper-reactive airways disease
H33z0 Status asthmaticus NOS
H33z0-1 Severe asthma attack
H33z1 Asthma attack
H33z1-1 Asthma attack NOS
H33z2 Late-onset asthma
H33zz Asthma NOS
H33zz-1 Exercise induced asthma
H33zz-2 Allergic asthma NEC
H33zz-3 Allergic bronchitis NEC
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with the study practices. Prescribing data were
also used to determine the total number of asthma-
related prescriptions issued by QRESEARCH
practices in each year of study.
All analyses were conducted using de-identified
data and were subject to the QRESEARCH research
governance process.
Definitions
Asthma was defined as patients who have Read
codes H33 and below (Box 1). Asthma-related
prescriptions were defined according to the new
General Medical Services contract.10 These drugs
included bronchodilators (BritishNational Formu-
lary [BNF] chapter 3.1), inhaled corticosteroids
(BNF chapter 3.2), and cromoglycates and related
therapies (BNF chapter 3.3). In England, these
drugs can only be prescribed by a clinician, usually
based in a primary care practice.
Statistical methods
As a result of known age and sex variations, rates
of disease and prescribing were standardized
by sex and five-year age bands. The mid-year
population estimates for England in each year of
studywere used as the reference population. These
results were then used to estimate the numbers of
people with asthma in England. Where appropri-
ate, 2 tests were used to test whether there
were statistical associations between categorical
variables. The Mantel-Haenszel 2 test was used
to investigate trends over time, this analysis
being undertaken using EpiInfo2000 (Centers for
Disease Control and Prevention, Atlanta, Georgia,
USA). Where appropriate, 95% confidence inter-
vals (95% CI) are reported.
Results
We estimated that 261,400 (95% CI 257,200–
265,700) of 50 million people in England were
newly diagnosed with asthma in 2005. We esti-
mated that 5,658,900 (95% CI 5,639,700–5,678,200)
had a GP recorded diagnosis of asthma, this trans-
lating into approximately one person in nine being
diagnosed with asthma at some point in their
lives. An estimated 3,257,000 (95% CI 3,242,400–
3,271,600) people with asthma were prescribed an
asthma-related drug. An estimated total of
32,577,300 (95% CI 32,531,600–32,623,000) asthma-
related prescriptions were issued to patients in
England in 2005.
Trends in incidence rate
Between 2001 and 2005, there was a decrease in
the incidence rate of asthma in England (Table 1).
Decreases in incidence were found in all groups of
patients, the largest of which was in pre-school
children (i.e. <5 years; Table 2). The incidence rate
Table 1
Incidence and lifetime prevalence rates of asthma 2001–2005
Year Total patients
(n)
Patients with
asthma (n)
Age–sex standardized rate per
1000 patient-years (95% CI)
Relative % change in
standardized rate (from 2001)
Incidence
2001 2,864,938 18,883 6.9 (6.8–7.0) 0
2002 2,890,190 18,611 6.7 (6.6–6.8) –2.7
2003 2,921,178 17,226 6.1 (6.1–6.2) –11.0
2004 2,922,024 17,947 6.4 (6.3–6.5) –7.8
2005 2,958,366 14,870 5.2 (5.1–5.3) –24.4
Lifetime prevalence
2001 2,864,938 285,941 100.5 (100.1–100.9)* 0
2002 2,890,190 301,048 104.8 (104.4–105.2)* 4.3
2003 2,921,178 315,559 108.5 (108.2–108.9)* 8.0
2004 2,922,024 325,857 111.9 (111.5–112.2) * 11.3
2005 2,958,366 333,294 113.0 (112.6–113.4) * 12.4
* Age–sex standardized rate per 1000 patients (95% CI)
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of asthma was highest in this age group (when
compared to older age groups) with one person in
70 being newly diagnosed in 2005.
Trends in lifetime prevalence
Over the study period, the recorded lifetime preva-
lence of asthma increased (Table 1). The recorded
lifetime prevalence for different groups of patients
with asthma can be seen in Table 3. School-aged
children (i.e. 5–14 years) had the highest lifetime
prevalence of asthma, with almost one in six hav-
ing been diagnosed with asthma at some point in
their lives. Significant decreases in lifetime preva-
lence over time were found in pre-school and
school-aged children (p<0.001). Significant in-
creases occurred in all other age groups (p<0.001).
Trends in asthma-related prescribing
The rate of asthma-related prescriptions per 1000
patients increased during the study period from
556.6 per 1000 (95%CI 554.7–556.4) in 2001 to 650.3
per 1000 patients (95% CI 649.4–651.2) in 2005, this
representing a 17.1% rise (p<0.001). Older patients
(>65 years) received the most prescriptions per
head of population (Table 4). Over the study
period, the rate of asthma-related prescriptions in-
creased in all groups except for pre-school children
Table 2
Incidence rate of asthma by gender, age and socioeconomic status
Group Year Total patients (n) New patients with
asthma (n)
Age–sex
standardized rate
per 1000 patient-
years (95% CI)*
Relative % change
in standardized
rate (from 2001)
Gender
Women 2001 1,444,314 10,241 7.3 (7.2–7.4)
2005 1,485,738 8159 5.6 (5.5–5.7) –23.2
Men 2001 1,420,624 8642 6.5 (6.4–6.6)
2005 1,472,628 6711 4.8 (4.7–4.9) –25.8
Age band (years)
0–4 2001 126,348 2891 22.9 (22.1–23.7)
2005 125,020 1781 14.3 (13.6–14.9) –38.4
5–14 2001 366,063 4153 11.4 (11.0–11.7)
2005 361,784 3033 8.4 (8.1–8.7) –27.0
15–44 2001 1,187,858 6248 5.3 (5.1–5.4)
2005 1,226,462 5459 4.5 (4.3–4.6) –12.6
45–64 2001 710,416 3429 4.8 (4.7–5.0)
2005 757,380 2892 3.8 (3.7–4.0) –15.7
65+ 2001 474,253 2162 4.6 (4.4–4.8)
2005 487,720 1705 3.5 (3.3–3.7) –21.1
Deprivation
Quintile 1† 2001 634,434 3785 6.3 (6.1–6.5)
2005 648,634 2834 4.6 (4.4–4.8) –26.5
Quintile 2 2001 565,812 3440 6.5 (6.2–6.7)
2005 580,431 2681 4.9 (4.7–5.1) –24.2
Quintile 3 2001 536,218 3489 6.9 (6.7–7.1)
2005 552,702 2783 5.3 (5.1–5.5) –22.9
Quintile 4 2001 497,925 3515 7.4 (7.1–7.6)
2005 515,271 2765 5.5 (5.3–5.8) –24.8
Quintile 5 2001 535,216 4139 8.0 (7.7–8.2)
2005 567,835 3361 6.0 (5.8–6.2) –24.2
* Crude rates are reported by age band
† Most affluent group of patients
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in whom there was a decrease in the rate of pre-
scribing for asthma treatments (p<0.001).
Socioeconomic variations
There were substantial socioeconomic differences
found in the rates of asthma, with the most de-
prived (quintile 5) having higher incidence (Table
2) and lifetime prevalence of asthma (Table 3) and
higher rates of being prescribed asthma-related
drugs (Table 4) than the most affluent patients
(quintile 1; p<0.001).
Discussion
This study, using routinely collected electronic
data from one of the world’s largest national
data-sets, has confirmed that asthma is extremely
common, and that despite an apparent decrease
in the number of people newly presenting with
the disease, the number of those with a lifetime
diagnosis and prescriptions of asthma-related
drugs issued by primary care continues to grow.
However, conversely, we have found evidence
that in children, the rate of new and lifetime
diagnosed prevalence of asthma and the issuing
of asthma-related prescriptions (for pre-school
children < 5 years) appears to be declining. Sub-
stantial socioeconomic differences were also
found in the rates of asthma, with the most
deprived having higher incidence and lifetime
prevalence of asthma and higher rates of being
prescribed an asthma-related drug.
Table 3
Lifetime prevalence rate of asthma by gender, age and socioeconomic status
Group Year Total patients
(n)
Patients with
asthma (n)
Age–sex standardized
rate per 1000 patients
(95% CI)*
Relative % change in
standardized rate
(from 2001)
Gender
Women 2001 1,444,314 145,253 100.6 (100.1–101.1)
2005 1,485,738 170,631 114.5 (113.9–115.0) 13.8
Men 2001 1,420,624 140,688 100.3 (99.8–100.9)
2005 1,472,628 162,663 111.4 (110.9–112.0) 25.8
Age band (years)
0–4 2001 126,348 7963 63.0 (61.7–64.6)
2005 125,020 5231 41.8 (40.7–43.0) –34.3
5–14 2001 366,063 59,285 161.9 (160.8–131.5)
2005 361,784 56,702 156.7 (155.5–157.9) –4.4
15–44 2001 1,187,858 126,226 106.3 (105.7–106.8)
2005 1,226,462 155,670 126.9 (126.3–127.5) 23.3
45–64 2001 710,416 53,951 75.9 (75.3–76.6)
2005 757,380 68,885 91.0 (90.3–91.6) 27.7
65+ 2001 474,253 38,516 81.2 (80.4–82.0)
2005 487,720 46,806 96.0 (95.1–96.8) 21.5
Deprivation
Quintile 1† 2001 634,434 60,048 97.7 (96.9–99.0)
2005 648,634 69,710 111.2 (110.3–112.0) 13.8
Quintile 2 2001 565,812 54,517 98.7 (97.9–99.6)
2005 580,431 63,721 112.4 (111.5–113.3) 13.8
Quintile 3 2001 536,218 54,041 101.7 (100.9–102.6)
2005 552,702 62,860 114.3 (113.4–115.2) 12.3
Quintile 4 2001 497,925 52,084 104.7 (103.8–105.6)
2005 515,271 60,718 117.3 (116.4–118.3) 12.1
Quintile 5 2001 535,216 57,122 106.5 (105.6–107.4)
2005 567,835 67,365 119.0 (118.1–119.9) 11.7
* Crude rates are reported by age band
† Most affluent group of patients
Journal of the Royal Society of Medicine
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Main strengths and limitations of this work
Themain strengths of this study include our inter-
rogation of patient-level computerized data from
an extremely large nationally representative data-
set, the fact that all contributing practices used the
same computing systems for electronically re-
cording clinical data, the approach used to ensure
that all contributing practices were accustomed
to electronically recording routine data, and the
use of contemporaneous clinician recording of a
diagnosis of asthma as opposed to patient self-
or parental reporting of historical diagnoses or
symptoms. The study design employed ensured
that there was no risk of selection bias due to
non-responders or recall bias.
There are a number of limitations related to the
use of large routinely collected data from primary
care, including the dependence on clinician-
recorded diagnosis of asthma (especially as diag-
nostic tests [e.g. spirometry] used to confirm or
refute diagnoses were not available), possible
improvements in recording over the study time
period and a lack of information on the dispensing
of drugs from pharmacies or evidence of patient
adherence to prescribed medications. The rela-
tively short time window over which trends were
studied is another limitation, and although this did
have the advantage of confining analysis to a
period during which there were relatively few
changes in disease definition, the introduction of
the new General Medical Services Contract to UK
Table 4
Asthma-related prescribing by gender, age and socioeconomic status
Group Year Total patients
(n)
Prescriptions
(n)
Prescriptions per 1000
patients per year
(95% CI)*
Relative % change in
standardized rate
(from 2001)
Gender
Women 2001 1,444,314 865,409 587.3 (586.1–588.6)
2005 1,485,738 1,076,906 709.4 (708.1–710.8) 20.8
Men 2001 1,420,624 751,682 522.4 (521.2–523.6)
2005 1,472,628 882,996 588.9 (587.6–590.1) 12.7
Age band (years)
0–4 2001 126,348 32,870 260.2 (257.7–262.8)
2005 125,020 25,896 207.1 (204.9–209.4) −21.2
5–14 2001 366,063 174,124 475.7 (474.1–477.3)
2005 361,784 177,625 490.1 (489.3–492.6) 2.0
15–44 2001 1,187,858 443,838 373.7 (372.8–374.5)
2005 1,226,462 529,168 431.4 (430.6–432.3) 19.2
45–64 2001 710,416 445,052 626.5 (625.3–627.6)
2005 757,380 576,942 761.8 (760.8–762.7) 29.6
65+ 2001 474,253 521,207 1099.0 (1096.0–1102.0)
2005 487,720 650,271 1333.3 (1330.0–1336.5) 24.8
Deprivation
Quintile 1† 2001 634,434 306,829 468.1 (466.4–469.8)
2005 648,634 371,855 541.9 (540.1–543.7) 15.8
Quintile 2 2001 565,812 292,763 499.8 (498.0–501.7)
2005 580,431 357,904 583.8 (581.9–585.8) 16.8
Quintile 3 2001 536,218 309,274 561.8 (559.8–563.8)
2005 552,702 375,716 659.1 (657.0–661.2) 17.3
Quintile 4 2001 497,925 313,379 635.9 (633.7–638.1)
2005 515,271 375,532 749.3 (746.9–751.7) 17.8
Quintile 5 2001 535,216 358,819 719.8 (717.4–722.1)
2005 567,835 438,293 865.1 (862.5–867.7) 20.2
* Crude rates are reported by age band
† Most affluent group of patients
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primary care in April 2004, which introduced
incentives to create and maintain a registry of
patients with asthma (aged over 8 years and with
one asthma-related prescription), may have influ-
enced the prevalence of asthma toward the latter
end of the study period. Data regarding childhood
incidence and prevalence may be underestimated,
as the ascertainment of disease present in the com-
munity will be dependent on parents bringing
their children for consultation.11 The inadequacy
of Read codes for asthma (as well as other allergy-
related conditions) has previously been reported
and this may have contributed to under-
recording.12 Prescribing data are not available by
clinical indication and, therefore, it is possible that
for a proportion of older patients, prescriptions for
other respiratory diseases such as chronic obstruc-
tive pulmonary disease are included.
Comparison of findings with other
published work
Our findings suggest that the increasing trend in
lifetime physician-diagnosed asthma found in
repeated surveys (Table 5) and by the large UK
electronic General Practice Research Database
(GPRD) between 1990 and 1998 (5% to 9%) contin-
ued between 2001 and 2005 in the QRESEARCH
database (10% to 11%).13 Recent declines that
were found in the incidence of asthma for school-
age children aged 5–14 years (GPRD 1990–1998:
3.2% to 1.5%) appear also to have continued
(QRESEARCH 2001–2005: 1.1% to 0.8%). A de-
clining prevalence of asthma in children has been
reported during a similar time period (2000–
2005) in Australia.14 Our estimated rate of 34
million prescriptions in 2005 is somewhat lower
than reported elsewhere (39.8 million).3 The as-
sociation of asthma incidence and prevalence
with socioeconomic deprivation has been pre-
viously described.15
Meaning of the study results: possible
mechanisms and implications for
clinicians and policymakers
Our data could be interpreted as indicating that
asthma may now be decreasing in children.
However, these results need to be interpreted in
the context of other studies, which have reported
Table 5
Comparison of UK epidemiological data for asthma
Source Time
period
Age group Outcome measured Results Change
over time
MSGP326 1981–1982 All patients Patients with a new episode of asthma 19.2 per
1000
14.7 per
1000
MSGP427 1991–1992 All patients Patients with a new episode of asthma 33.9 per
1000
ISAAC Phase One28 1995–1996 6–7 years 12-month period prevalence self-reported
wheezing or whistling in UK
18.4% 2.5%
ISAAC Phase Three28 2002–2003 6–7 years 12-month period prevalence self-reported
wheezing or whistling in UK
20.9%
ISAAC Phase One28 1995–1996 13–14 years 12-month period prevalence self-reported
wheezing or whistling in UK
31.0% –6.3%
ISAAC Phase Three28 2002–2003 13–14 years 12-month period prevalence self-reported
wheezing or whistling in UK
24.7%
Aberdeen School
Children Cohort29
1964–1999 10.6 years
(mean)
Self-reported prevalence of ever having asthma 4.0% to
24.0%
20.0%
HSE30 1995–1996 Men Lifetime prevalence of doctor-diagnosed asthma 11.0% 2.0%
HSE30 2000–2001 Men Lifetime prevalence of doctor-diagnosed asthma 13.0%
HSE30 1995–1996 Women Lifetime prevalence of doctor-diagnosed asthma 12.0% 4.0%
HSE30 2000–2001 Women Lifetime prevalence of doctor-diagnosed asthma 16.0%
MSGP – Morbidity Statistics from General Practice; ISAAC – The International Study of Asthma and Allergies in Childhood;
HSE – Health Survey for England
Journal of the Royal Society of Medicine
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increases over the same time period (using
QRESEARCH data) in the prevalence of eczema,
allergic rhinitis and multiple allergies in
children,7–9 increases in atopic sensitization in re-
peated UK birth cohorts over a 25-year window,16
and increases in the prevalence of asthma glo-
bally.17 It is, therefore, likely that rather than a
reduction of more persistent wheezing associated
with allergic sensitization (i.e. the ‘classic’ asthma
phenotype),18 what we may be witnessing is the
impact of revised national asthma guidelines,19
with the recognition that infants and pre-school
children who wheeze may not be asthmatics, but
are wheezing secondary to small airway or respirat-
ory viral infections thus resulting in a diagnostic
shift from ‘asthma’ to labels such as ‘wheeze’ or
‘acute respiratory infection’.20 For adults, the reduc-
tion in incidence rates could also reflect a growing
concern that, after years of under-diagnosis, asthma
may now be over-diagnosed in primary care.10 It is
also possible that the observed changes in disease
incidence and prevalence could have been affected
by the introduction of the new incentivized
General Medical Services contract, whereby pay-
ments are made to practices to keep accurate regis-
ters of patients with diseases such as asthma.21
However, despite these changes in recorded inci-
dence, increases in the lifetime prevalence of
asthma and asthma-related prescribing appears to
be continuing, such that by 2005 an estimated 5.7
million people in England were diagnosed with
asthma, with over half of these (3 million) requir-
ing recent medical treatment. It is possible that this
is the result of changes in environmental factors
over time which has favoured the expression
of allergic disease in those who are genetically
susceptible.22 However, it is also possible that
increases in the rate of these conditions could have
resulted from increased clinician awareness of
allergic problems, which may then have led to
improved identification and recording of asthma.
Similarly, increased patient awareness of the
potential of accessing effective treatmentsmay have
resulted in increased case presentation and pre-
scribing in primary care. Although data were not
available on smoking, it is likely that higher rates
of smoking among the more socioeconomically-
deprived groups of patients23 will have contrib-
uted to the substantial socioeconomic differences
found in the rates of asthma and asthma-related
prescribing.
Whatever the cause, the increasing number of
people with asthma in England poses a substantial
disease burden on primary care services.24,25
Conclusions and future research
This large national study reveals that the rate of
new diagnoses of asthma appears to have passed
its peak. However, the number of adults with a
lifetime asthma diagnosis continues to rise.
Whether these trends are genuine or are a result of
the introduction of incentives and guidelines to
improve identification and recording of asthma or
changing diagnostic trends is a question with im-
portant public health implications and one, there-
fore, that warrants detailed further enquiry.
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